A Discrete Choice Conjoint Experiment to Evaluate Parent Preferences for Treatment of Young, Medication Naive Children with ADHD / Daniel A. WASCHBUSCH in Journal of Clinical Child & Adolescent Psychology, 40-4 (July-August 2011)  

Public ISBD [article]  inJournal of Clinical Child & Adolescent Psychology > 40-4 (July-August 2011) . - p.546-561 Titre : A Discrete Choice Conjoint Experiment to Evaluate Parent Preferences for Treatment of Young, Medication Naive Children with ADHD Type de document : texte imprimé Auteurs : Daniel A. WASCHBUSCH, Auteur ; Charles E. CUNNINGHAM, Auteur ; William E. PELHAM, Auteur ; Heather L. RIMAS, Auteur ; Andrew R. GREINER, Auteur ; Elizabeth M. GNAGY, Auteur ; James WAXMONSKY, Auteur ; Gregory A. FABIANO, Auteur ; Jessica A. ROBB, Auteur ; Lisa BURROWS-MACLEAN, Auteur ; Mindy SCIME, Auteur ; Martin T. HOFFMAN, Auteur Année de publication : 2011 Article en page(s) : p.546-561 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : The current study examined treatment preferences of 183 parents of young (average age = 5.8 years, SD = 0.6), medication naive children with ADHD. Preferences were evaluated using a discrete choice experiment in which parents made choices between different combinations of treatment characteristics, outcomes, and costs. Latent class analysis yielded two segments of parents: (a) medication avoidant parents constituted 70.5% of the sample whose treatment decisions were strongly influenced by a desire to avoid medication, and (b) outcome oriented parents constituted 29.5% of the sample whose treatment decisions were most influenced by a desire for positive treatment outcomes. Parents in the outcome oriented segment were more stressed and depressed, had lower socioeconomic status and education, were more likely to be single parents, and had more disruptive and impaired children. Simulations predicted that parents would prefer treatments with behavior therapy over treatments with stimulant medication only. En ligne : http://dx.doi.org/10.1080/15374416.2011.581617 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=132 [article] A Discrete Choice Conjoint Experiment to Evaluate Parent Preferences for Treatment of Young, Medication Naive Children with ADHD [texte imprimé] / Daniel A. WASCHBUSCH, Auteur ; Charles E. CUNNINGHAM, Auteur ; William E. PELHAM, Auteur ; Heather L. RIMAS, Auteur ; Andrew R. GREINER, Auteur ; Elizabeth M. GNAGY, Auteur ; James WAXMONSKY, Auteur ; Gregory A. FABIANO, Auteur ; Jessica A. ROBB, Auteur ; Lisa BURROWS-MACLEAN, Auteur ; Mindy SCIME, Auteur ; Martin T. HOFFMAN, Auteur . - 2011 . - p.546-561. Langues : Anglais (eng) in Journal of Clinical Child & Adolescent Psychology > 40-4 (July-August 2011) . - p.546-561 Index. décimale : PER Périodiques Résumé : The current study examined treatment preferences of 183 parents of young (average age = 5.8 years, SD = 0.6), medication naive children with ADHD. Preferences were evaluated using a discrete choice experiment in which parents made choices between different combinations of treatment characteristics, outcomes, and costs. Latent class analysis yielded two segments of parents: (a) medication avoidant parents constituted 70.5% of the sample whose treatment decisions were strongly influenced by a desire to avoid medication, and (b) outcome oriented parents constituted 29.5% of the sample whose treatment decisions were most influenced by a desire for positive treatment outcomes. Parents in the outcome oriented segment were more stressed and depressed, had lower socioeconomic status and education, were more likely to be single parents, and had more disruptive and impaired children. Simulations predicted that parents would prefer treatments with behavior therapy over treatments with stimulant medication only. En ligne : http://dx.doi.org/10.1080/15374416.2011.581617 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=132

Disruptive mood dysregulation disorder (DMDD) symptoms in children with autism, ADHD, and neurotypical development and impact of co-occurring ODD, depression, and anxiety / Susan D. MAYES in Research in Autism Spectrum Disorders, 18 (October 2015)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 18 (October 2015) . - p.64-72 Titre : Disruptive mood dysregulation disorder (DMDD) symptoms in children with autism, ADHD, and neurotypical development and impact of co-occurring ODD, depression, and anxiety Type de document : texte imprimé Auteurs : Susan D. MAYES, Auteur ; James WAXMONSKY, Auteur ; Susan L. CALHOUN, Auteur ; C. KOKOTOVICH, Auteur ; C. MATHIOWETZ, Auteur ; Raman BAWEJA, Auteur Article en page(s) : p.64-72 Langues : Anglais (eng) Mots-clés : Disruptive mood dysregulation disorder  Autism  ADHD  ODD  Neurotypical Index. décimale : PER Périodiques Résumé : Abstract Disruptive mood dysregulation disorder (DMDD) is a controversial diagnosis introduced in the DSM-5 that is particularly relevant to autism and other disorders in which DMDD symptoms (irritable-angry mood and temper outbursts) are common. Mothers rated DMDD symptoms in 1593 children with autism, ADHD, and neurotypical development (6–16 years, IQ ≥ 80). Percentages with DMDD symptoms (often or very often) were autism 45%, ADHD-Combined type 39%, ADHD-Inattentive type 12%, and neurotypical 3%. Almost all (91%) with DMDD symptoms met DSM-5 criteria for ODD, and 79% with ODD had DMDD symptoms. Only 5% without ODD had DMDD symptoms, and most of these had autism. Children with autism had significantly higher DMDD scores than all other groups, even when the oppositional behavior score (excluding the two DMDD symptoms) was controlled. The findings suggest that DMDD and ODD are not meaningfully differentiated based on their symptoms and that DMDD symptoms are particularly common in autism, more so than expected by comorbid ODD alone. En ligne : http://dx.doi.org/10.1016/j.rasd.2015.07.003 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=268 [article] Disruptive mood dysregulation disorder (DMDD) symptoms in children with autism, ADHD, and neurotypical development and impact of co-occurring ODD, depression, and anxiety [texte imprimé] / Susan D. MAYES, Auteur ; James WAXMONSKY, Auteur ; Susan L. CALHOUN, Auteur ; C. KOKOTOVICH, Auteur ; C. MATHIOWETZ, Auteur ; Raman BAWEJA, Auteur . - p.64-72. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 18 (October 2015) . - p.64-72 Mots-clés : Disruptive mood dysregulation disorder  Autism  ADHD  ODD  Neurotypical Index. décimale : PER Périodiques Résumé : Abstract Disruptive mood dysregulation disorder (DMDD) is a controversial diagnosis introduced in the DSM-5 that is particularly relevant to autism and other disorders in which DMDD symptoms (irritable-angry mood and temper outbursts) are common. Mothers rated DMDD symptoms in 1593 children with autism, ADHD, and neurotypical development (6–16 years, IQ ≥ 80). Percentages with DMDD symptoms (often or very often) were autism 45%, ADHD-Combined type 39%, ADHD-Inattentive type 12%, and neurotypical 3%. Almost all (91%) with DMDD symptoms met DSM-5 criteria for ODD, and 79% with ODD had DMDD symptoms. Only 5% without ODD had DMDD symptoms, and most of these had autism. Children with autism had significantly higher DMDD scores than all other groups, even when the oppositional behavior score (excluding the two DMDD symptoms) was controlled. The findings suggest that DMDD and ODD are not meaningfully differentiated based on their symptoms and that DMDD symptoms are particularly common in autism, more so than expected by comorbid ODD alone. En ligne : http://dx.doi.org/10.1016/j.rasd.2015.07.003 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=268

How do stimulant treatments for ADHD work? Evidence for mediation by improved cognition / Larry W. HAWK in Journal of Child Psychology and Psychiatry, 59-12 (December 2018)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 59-12 (December 2018) . - p.1271-1281 Titre : How do stimulant treatments for ADHD work? Evidence for mediation by improved cognition Type de document : texte imprimé Auteurs : Larry W. HAWK, Auteur ; Whitney D. FOSCO, Auteur ; Craig R. COLDER, Auteur ; James G. WAXMONSKY, Auteur ; W.E. PELHAM, Auteur ; Keri S. ROSCH, Auteur Article en page(s) : p.1271-1281 Langues : Anglais (eng) Mots-clés : Attention-Deficit/Hyperactivity Disorder  cognition  mediation  methylphenidate Index. décimale : PER Périodiques Résumé : BACKGROUND: Stimulant medications such as methylphenidate (MPH) are the frontline treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). Despite their well-documented efficacy, the mechanisms by which stimulants improve clinical outcomes are not clear. The current study evaluated whether MPH effects on classroom behavior were mediated by improved cognitive functioning. METHODS: Children with ADHD (n = 82; 9-12 years old) participated in a week-long summer research camp, consisting of cognitive testing, classroom periods, and recreational activities. After a baseline day, participants completed a 3-day randomized, double-blind, placebo-controlled trial of MPH (at doses approximating 0.3 and 0.6 mg/kg of immediate-release MPH dosed TID). Cognitive domains included inhibitory control (Stop Signal Task and prepulse inhibition of startle), attention (Continuous Performance Task and reaction time variability), and working memory (forward and backward spatial span). Clinical outcomes included math seatwork productivity and teacher-rated classroom behavior. A within-subjects path-analytic approach was used to test mediation. MPH-placebo and dose-response contrasts were used to evaluate drug effects. RESULTS: Methylphenidate improved seatwork productivity and teacher ratings (ds = 1.4 and 1.1) and all domains of cognition (ds = 0.3-1.1). Inhibitory control (Stop Signal Task, SST) and working memory backward uniquely mediated the effect of MPH (vs. placebo) on productivity. Only working memory backward mediated the impact of MPH on teacher-rated behavior. The dose-response (0.6 vs. 0.3 mg/kg) effects were more modest for clinical outcomes (ds = 0.4 and 0.2) and cognition (ds = 0-0.3); there was no evidence of cognitive mediation of the clinical dose-response effects. CONCLUSIONS: These findings are novel in demonstrating that specific cognitive processes mediate clinical improvement with stimulant treatment for ADHD. They converge with work on ADHD theory, neurobiology, and treatment development in suggesting that inhibitory control and working memory may be mechanisms of stimulant treatment response in ADHD. More work is necessary to evaluate the degree to which these findings generalize to chronic treatment, a broader array of clinical outcomes, and nonstimulant treatments. En ligne : http://dx.doi.org/10.1111/jcpp.12917 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=371 [article] How do stimulant treatments for ADHD work? Evidence for mediation by improved cognition [texte imprimé] / Larry W. HAWK, Auteur ; Whitney D. FOSCO, Auteur ; Craig R. COLDER, Auteur ; James G. WAXMONSKY, Auteur ; W.E. PELHAM, Auteur ; Keri S. ROSCH, Auteur . - p.1271-1281. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 59-12 (December 2018) . - p.1271-1281 Mots-clés : Attention-Deficit/Hyperactivity Disorder  cognition  mediation  methylphenidate Index. décimale : PER Périodiques Résumé : BACKGROUND: Stimulant medications such as methylphenidate (MPH) are the frontline treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). Despite their well-documented efficacy, the mechanisms by which stimulants improve clinical outcomes are not clear. The current study evaluated whether MPH effects on classroom behavior were mediated by improved cognitive functioning. METHODS: Children with ADHD (n = 82; 9-12 years old) participated in a week-long summer research camp, consisting of cognitive testing, classroom periods, and recreational activities. After a baseline day, participants completed a 3-day randomized, double-blind, placebo-controlled trial of MPH (at doses approximating 0.3 and 0.6 mg/kg of immediate-release MPH dosed TID). Cognitive domains included inhibitory control (Stop Signal Task and prepulse inhibition of startle), attention (Continuous Performance Task and reaction time variability), and working memory (forward and backward spatial span). Clinical outcomes included math seatwork productivity and teacher-rated classroom behavior. A within-subjects path-analytic approach was used to test mediation. MPH-placebo and dose-response contrasts were used to evaluate drug effects. RESULTS: Methylphenidate improved seatwork productivity and teacher ratings (ds = 1.4 and 1.1) and all domains of cognition (ds = 0.3-1.1). Inhibitory control (Stop Signal Task, SST) and working memory backward uniquely mediated the effect of MPH (vs. placebo) on productivity. Only working memory backward mediated the impact of MPH on teacher-rated behavior. The dose-response (0.6 vs. 0.3 mg/kg) effects were more modest for clinical outcomes (ds = 0.4 and 0.2) and cognition (ds = 0-0.3); there was no evidence of cognitive mediation of the clinical dose-response effects. CONCLUSIONS: These findings are novel in demonstrating that specific cognitive processes mediate clinical improvement with stimulant treatment for ADHD. They converge with work on ADHD theory, neurobiology, and treatment development in suggesting that inhibitory control and working memory may be mechanisms of stimulant treatment response in ADHD. More work is necessary to evaluate the degree to which these findings generalize to chronic treatment, a broader array of clinical outcomes, and nonstimulant treatments. En ligne : http://dx.doi.org/10.1111/jcpp.12917 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=371

Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression / James M. SWANSON in Journal of Child Psychology and Psychiatry, 58-6 (June 2017)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 58-6 (June 2017) . - p.663-678 Titre : Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression Type de document : texte imprimé Auteurs : James M. SWANSON, Auteur ; L. Eugene ARNOLD, Auteur ; Brooke S.G. MOLINA, Auteur ; Margaret H. SIBLEY, Auteur ; Lily HECHTMAN, Auteur ; Stephen P. HINSHAW, Auteur ; Howard B. ABIKOFF, Auteur ; Annamarie STEHLI, Auteur ; Elizabeth B. OWENS, Auteur ; John T. MITCHELL, Auteur ; Quyen NICHOLS, Auteur ; Andrea L. HOWARD, Auteur ; Laurence L. GREENHILL, Auteur ; Betsy HOZA, Auteur ; Jeffrey H. NEWCORN, Auteur ; Peter S. JENSEN, Auteur ; Benedetto VITIELLO, Auteur ; Timothy WIGAL, Auteur ; Jeffery N. EPSTEIN, Auteur ; Leanne TAMM, Auteur ; Kimberly D. LAKES, Auteur ; James WAXMONSKY, Auteur ; Marc LERNER, Auteur ; Joy ETCOVITCH, Auteur ; Desiree W. MURRAY, Auteur ; Maximilian MUENKE, Auteur ; Maria T. ACOSTA, Auteur ; Mauricio ARCOS-BURGOS, Auteur ; William E. PELHAM, Auteur ; Helena C. KRAEMER, Auteur ; THE MTA COOPERATIVE GROUP, Auteur Article en page(s) : p.663-678 Langues : Anglais (eng) Mots-clés : Attention-deficit/hyperactivity disorder  follow-up studies  growth  longitudinal studies  treatment trials  medication effects Index. décimale : PER Périodiques Résumé : Background The Multimodal Treatment Study (MTA) began as a 14-month randomized clinical trial of behavioral and pharmacological treatments of 579 children (7–10 years of age) diagnosed with attention-deficit/hyperactivity disorder (ADHD)-combined type. It transitioned into an observational long-term follow-up of 515 cases consented for continuation and 289 classmates (258 without ADHD) added as a local normative comparison group (LNCG), with assessments 2–16 years after baseline. Methods Primary (symptom severity) and secondary (adult height) outcomes in adulthood were specified. Treatment was monitored to age 18, and naturalistic subgroups were formed based on three patterns of long-term use of stimulant medication (Consistent, Inconsistent, and Negligible). For the follow-up, hypothesis-generating analyses were performed on outcomes in early adulthood (at 25 years of age). Planned comparisons were used to estimate ADHD-LNCG differences reflecting persistence of symptoms and naturalistic subgroup differences reflecting benefit (symptom reduction) and cost (height suppression) associated with extended use of medication. Results For ratings of symptom severity, the ADHD-LNCG comparison was statistically significant for the parent/self-report average (0.51 ± 0.04, p < .0001, d = 1.11), documenting symptom persistence, and for the parent/self-report difference (0.21 ± 0.04, p < .0001, d = .60), documenting source discrepancy, but the comparisons of naturalistic subgroups reflecting medication effects were not significant. For adult height, the ADHD group was 1.29 ± 0.55 cm shorter than the LNCG (p < .01, d = .21), and the comparisons of the naturalistic subgroups were significant: the treated group with the Consistent or Inconsistent pattern was 2.55 ± 0.73 cm shorter than the subgroup with the Negligible pattern (p < .0005, d = .42), and within the treated group, the subgroup with the Consistent pattern was 2.36 ± 1.13 cm shorter than the subgroup with the Inconsistent pattern (p < .04, d = .38). Conclusions In the MTA follow-up into adulthood, the ADHD group showed symptom persistence compared to local norms from the LNCG. Within naturalistic subgroups of ADHD cases, extended use of medication was associated with suppression of adult height but not with reduction of symptom severity. En ligne : http://dx.doi.org/10.1111/jcpp.12684 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=308 [article] Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression [texte imprimé] / James M. SWANSON, Auteur ; L. Eugene ARNOLD, Auteur ; Brooke S.G. MOLINA, Auteur ; Margaret H. SIBLEY, Auteur ; Lily HECHTMAN, Auteur ; Stephen P. HINSHAW, Auteur ; Howard B. ABIKOFF, Auteur ; Annamarie STEHLI, Auteur ; Elizabeth B. OWENS, Auteur ; John T. MITCHELL, Auteur ; Quyen NICHOLS, Auteur ; Andrea L. HOWARD, Auteur ; Laurence L. GREENHILL, Auteur ; Betsy HOZA, Auteur ; Jeffrey H. NEWCORN, Auteur ; Peter S. JENSEN, Auteur ; Benedetto VITIELLO, Auteur ; Timothy WIGAL, Auteur ; Jeffery N. EPSTEIN, Auteur ; Leanne TAMM, Auteur ; Kimberly D. LAKES, Auteur ; James WAXMONSKY, Auteur ; Marc LERNER, Auteur ; Joy ETCOVITCH, Auteur ; Desiree W. MURRAY, Auteur ; Maximilian MUENKE, Auteur ; Maria T. ACOSTA, Auteur ; Mauricio ARCOS-BURGOS, Auteur ; William E. PELHAM, Auteur ; Helena C. KRAEMER, Auteur ; THE MTA COOPERATIVE GROUP, Auteur . - p.663-678. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 58-6 (June 2017) . - p.663-678 Mots-clés : Attention-deficit/hyperactivity disorder  follow-up studies  growth  longitudinal studies  treatment trials  medication effects Index. décimale : PER Périodiques Résumé : Background The Multimodal Treatment Study (MTA) began as a 14-month randomized clinical trial of behavioral and pharmacological treatments of 579 children (7–10 years of age) diagnosed with attention-deficit/hyperactivity disorder (ADHD)-combined type. It transitioned into an observational long-term follow-up of 515 cases consented for continuation and 289 classmates (258 without ADHD) added as a local normative comparison group (LNCG), with assessments 2–16 years after baseline. Methods Primary (symptom severity) and secondary (adult height) outcomes in adulthood were specified. Treatment was monitored to age 18, and naturalistic subgroups were formed based on three patterns of long-term use of stimulant medication (Consistent, Inconsistent, and Negligible). For the follow-up, hypothesis-generating analyses were performed on outcomes in early adulthood (at 25 years of age). Planned comparisons were used to estimate ADHD-LNCG differences reflecting persistence of symptoms and naturalistic subgroup differences reflecting benefit (symptom reduction) and cost (height suppression) associated with extended use of medication. Results For ratings of symptom severity, the ADHD-LNCG comparison was statistically significant for the parent/self-report average (0.51 ± 0.04, p < .0001, d = 1.11), documenting symptom persistence, and for the parent/self-report difference (0.21 ± 0.04, p < .0001, d = .60), documenting source discrepancy, but the comparisons of naturalistic subgroups reflecting medication effects were not significant. For adult height, the ADHD group was 1.29 ± 0.55 cm shorter than the LNCG (p < .01, d = .21), and the comparisons of the naturalistic subgroups were significant: the treated group with the Consistent or Inconsistent pattern was 2.55 ± 0.73 cm shorter than the subgroup with the Negligible pattern (p < .0005, d = .42), and within the treated group, the subgroup with the Consistent pattern was 2.36 ± 1.13 cm shorter than the subgroup with the Inconsistent pattern (p < .04, d = .38). Conclusions In the MTA follow-up into adulthood, the ADHD group showed symptom persistence compared to local norms from the LNCG. Within naturalistic subgroups of ADHD cases, extended use of medication was associated with suppression of adult height but not with reduction of symptom severity. En ligne : http://dx.doi.org/10.1111/jcpp.12684 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=308

---

1 (1 - 4 / 4) Par page : 25 50 100 200